Jun Xiang, Ph.D., has 15 years’ experience in R&D of biological drug products, and is serving as the Vice President of Biotechnology Institute of Shanghai CP Guojian.
He is responsible for the research and development of novel formulations and drug delivery systems as well as late stage production processes for antibody drug products.
He is also in charge of the entire development of antibody-drug conjugates (ADC) and establishing ADC technology platform in CP Guojian. Dr. Xiang previously worked as a Staff Scientist and project leader at Bayer HealthCare Pharmaceuticals in US.
He has involved in the development of recombinant human factor VIII (KogenateÔ) and its next generation products, which is known as a rocket-science product in biopharmaceuticals, and multiple other protein drugs on the market and antibodies in the clinical development.
Dr. Xiang has tremendous experience in late stage development of biological drug products, especially in the various CMC fields, including formulation, drug delivery, aseptic filling, freeze-drying, final container closure and injection device, production process development, etc., and has 2 US patents granted and 15 international patents pending.
He served as the President of Chinese American Biopharmaceutical Society (CABS) headquartered in San Francisco Bay Area from 2005 to 2006, and has been serving as a Board of Director of CABS since 2004.
He was also the Chief Managing Editor of the journal Trends in Bio/pharmaceutical Industrial from 2008 to 2011.